Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Topline durability data for miv-cel support its potential as a single-dose treatment that could reduce patients’ lifelong disease burden and dependence on chronic immunotherapies. The results reinforce the therapy’s differentiated construct, although the article provides no quantitative efficacy, safety, or durability metrics.